Research team website  



Postdoctoral Researcher
16 parc du Cailly, 76130 MONT SAINT AIGNAN
+336-34-95-20-37 - This email address is being protected from spambots. You need JavaScript enabled to view it.

  - Burgundy University, Dijon, France -
• Ph.D. Neurosciences, 26 October 2018
• M.S. Neurosciences, June 2015
• D.E.S Innovation Pharmaceutique & Recherche, 19 October 2018

  - François Mitterrand Hospital, Dijon, France -
• PharmD, Neurology, 19 October 2018

Research Interests
• Neurotrophins
• Link between endothelial function and cognition
• Pathogenesis of neurodegenerative diseases
• Stroke physiopathology

Neurosciences Research Experience
• Inserm U1093, Dijon, France
Ph.D., 2015-2018
Thesis: Link between cardiovascular health and cognition. Role of endothelial BDNF
    Low cerebral levels of brain-derived neurotrophic factor (BDNF), which plays a critical role in many brain functions, have been implicated in neurodegenerative, neurological and psychiatric diseases. Thus, increasing BDNF levels in the brain is considered an attractive possibility for the prevention/treatment of various brain diseases. To date BDNF-based therapies have largely focused on neurons. However, given the cross-talk between endothelial cells and neurons and recent evidence that BDNF expressed by the cerebral endothelium largely accounts for BDNF levels present in the brain, it islikely that BDNF-based therapies would be most effective if they also targeted the cerebral endothelium.

• Inserm U1239, Rouen, France
Postdoctoral Researcher, 2018-present
Thematic: Urotensinergic system in cerebral vasospasm and inflammation: validation of potential therapeutic ligands in a mouse model of subarachnoid hemorrhage
    In subarachnoid hemorrhage (SAH), the mortality rate reaches as high as 30% within the first week, and 50% die in the first 6 months, with the main complication being delayed cerebral ischemia, due to cerebral vasospasm (CVS) and/or microthrombosis. Microthrombi may result from local vascular inflammation, overexpression of endothelial adhesion molecules, likely responsible for unfavorable patient outcome. Based on preliminary results showing that the vasoactive peptide urotensin II (UII) in SAH patient constitutes a diagnostic marker of CVS and that a UII receptor (UT) ligand prevents CVS in a SAH mouse model, our objectives are to i) investigate the UII-induced CVS, apoptosis and neurobehavior in UT+/+, UT-/- or humanized UTh+/h+ SAH mice, and in vivo neuroinflammation through MPIO targeted against endothelial adhesion molecules for MRI in these animals (WP1), ii) establish endothelial cells integrity and UT signaling signature (BRET and FRET-HTRF) activated by newly designed ligands (WP2) and iii) evaluate these UT ligands on CVS, apoptosis and neuroinflammation as well as neurobehavior of UT-/- and UTh+/h+ SAH mice. At the end of the project, we expect to propose that plasma UII dosage in the acute phase of SAH allows risk stratification and expedites the implementation of a treatment targeting the urotensinergic system in SAH patients.


  1. Pedard, M., Demougeot, C., Prati, C., and Marie, C. (2017). Brain-derived neurotrophic factor in adjuvant-induced arthritis in rats. Relationship with inflammation and endothelial dysfunction. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 82:249-254.
  2. Pedard, M., Quirié, A., Garnier, P., Tessier, A., Demougeot, C., Prati, C., and Marie, C. (2017). The cerebral brain-derived neurotrophic factor pathway, either neuronal or endothelial, is impaired in rats with adjuvant induced arthritis. Connection with endothelial dysfunction. Frontiers in Physiology. DOI:10.3389/fphya2D17.01175.
  3. Totoson, P., Pedard, M., Marie, C., and Demougeot, C. (2018). Activation of endothelial TrkB receptors induces relaxation of resistance arteries. Vascular Pharmacology. 106:46-43.
  4. Pedard, M., Quirié, A., Totoson, P., Verhoeven, F., Garnier, P., Tessier, A., Demougeot, C., and Marie, C. (2018). Vascular brain-derived neurotrophic factor pathway in rats with adjuvant-induced arthritis. Effect of anti-rheumatic drugs. Atherosclerosis. 274:77-85.
  5. Marie, C., Pedard, M., Quirié, A., Tessier, A., Garnier, P., Totoson, P., and Demougeot, C. (2018). Brain derived neurotrophic factor secreted by the cerebral endothelium : a new actor of brain function ? Journal of Cerebral Blood Flow and Metabolism. 38:935-949.
  6. Pedard, M., Cefis, M., Ennequin, G., Quirié, A., Garnier, P., Tessier, A., Pernet, N., and Marie, C. (2018). Brain-derived neurotrophic factor pathway after downhill and uphill training in rats. Medicine and Science in Sports and Exercise. 51:27-34.
  7. Pedard, M., Brenière, C., Pernet, N., Vergely, C., Bejot, Y., and Marie, C. (2018). Brain-derived neurotrophic factor in peripheral blood mononuclear cells and stroke outcome. Experimental Biology & Medicine. doi: 10.1177/1535370218815612
  8. Breniere, C., Meloux, A., Pedard, M., Marie, C., Thouant, P., Vergely, C., and Bejot, Y. (2019). Growth Differentiation Factor-15 (GDF-15) is associated with mortality in ischemic stroke patients treated with acute revascularization therapy. Frontiers in Neurology. doi: 10.3389/fneur.2019.00611

International Communications

  1. Pedard, M., Totoson, P., Prati, C., Demougeot, C., and Marie, C. (2016). Impaired cognition is linked to brain depletion in BDNF levels in a rat model of rheumatoid arthritis. Arthritis Rheumatol 68(Supplement 10). ACR/ARHP Annual Scientific Meeting, Washington, USA, november 2016 (poster).
  2. Pedard, M., Ennequin, G., and Marie, C. (2017). Effects of eccentric and concentric training on brain-derived neurotrophic factor signaling in cognition-related brain regions. Acta Physiologica 221(Supplement S713). FEPS Congress, Vienna, Austria, september 2017 (oral communication).
  3. Pedard, M., Ennequin, G., and Marie, C. (2017). Effects of eccentric and concentric training on BDNF/TrkB signaling in cognition-related brain regions. Movement & Sport Sciences – Science et Motricité 95. ACAPS Congress, Dijon, France, october 2017 (oral communication).
  4. Pedard, M., Clavier, T., Mutel, A., Desrues, L., Lefevre-Scelles, A., Gastaldi, G., El Amki, M., Dubois, M., Melot, A., Curey, S., Gérardin, E., Proust, F., Compère, V., and Castel, H. (2019). Vasoactive peptide urotensin II in plasma is associated with cerebral vasospasm after aneurysmal subarachnoid hemorrhage and constitutes a potential therapeutic target. NeuroFrance 2019, Marseille, France, may 2019 (poster).